Related Experiment Video

Updated: Jan 17, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.4K

Spesolimab for a child with generalized pustular psoriasis accompanied epilepsy and hyperactivity

Yudan Wang1, Jie Qin1, Li Peng1

  • 1Department of Dermatology, Chengdu Second People's Hospital, Sichuan Province.

The Journal of Dermatological Treatment
|September 23, 2025
PubMed

Insights

Spesolimab effectively treated a pediatric patient with Generalized Pustular Psoriasis (GPP). Symptoms like pustules and erythema resolved rapidly within a week, indicating its therapeutic potential.

Area of Science:

  • Dermatology
  • Genetics
  • Pediatrics

Background:

  • Generalized Pustular Psoriasis (GPP) is a rare, severe skin condition.
  • Pediatric GPP cases are challenging to treat, especially when refractory.
  • Genetic mutations in IL36RN can contribute to GPP pathogenesis.

Purpose of the Study:

  • To evaluate the efficacy and safety of spesolimab for treating pediatric GPP.
  • To assess the treatment response in a young patient with refractory GPP and comorbidities.

Main Methods:

  • Case report of a 10-year-old male with refractory GPP.
  • Genetic analysis revealed IL36RN mutations (c.115+6T>C homozygous and c.227C>T heterozygous).
  • Treatment with spesolimab was administered.

Main Results:

  • Spesolimab treatment led to a complete and rapid response in the pediatric GPP patient.
  • Pustules, erythema, and scaling resolved within one week of treatment initiation.
  • The patient tolerated spesolimab well, showing significant clinical improvement.

Conclusions:

  • Spesolimab demonstrates significant therapeutic efficacy in pediatric GPP.
  • It represents a promising future treatment strategy for pediatric GPP.
  • Targeting IL-36 signaling pathway is effective for GPP management.
Abstract

Keywords:
ADHDPexolimabSpesolimabchildrenepilepsyimpetigo

More Related Videos

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.4K
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy07:20

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy

Published on: August 9, 2024

1.8K

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
831
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
499
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493